Gionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
|
|
- Gabriel Dorsey
- 6 years ago
- Views:
Transcription
1 Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico
2 Anti cell adhesion molecules Danese S, NEJM 2011
3 6 Steps leukocyte recruitment Fiorino G. et al. 2010
4 Vedolizumab Blocks Fewer Biological Pathways than Natalizumab MadCAM-1 Source: Soler, 2009 and TYSABRI prescribing information. BB-012
5 Vedolizumab Induction and Maintenance Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo Controlled, Double Blind, Multicenter Phase 3 Trial Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands, William Sandborn, Jean Frederic Colombel, Stephen Hanauer, Gert Van Assche, Jeffrey Axler, Hyo Jong Kim, Silvio i Danese, Irving Fox, Catherine Cth Milch, Serap Sankoh, Tim Wyant, Jing Xu, and Asit Parikh
6 Pi Primary and Secondary Outcomes Induction Primary: clinical response at 6 weeks Secondary: clinical remission at 6 weeks; mucosal healing at 6 weeks Maintenance Primary: clinical remission at 52 weeks Secondary: durability of clinical response; durability of clinical remission; mucosal healing at 52 weeks; corticosteroid free remission at 52 weeks Definitions: Clinical response = reduction in complete Mayo score of 3 points and 30% + decrease in rectal bleeding subscore of 1 point or absolute rectal bleeding subscore of 1 point Clinical remission = complete Mayo score of 2 points and no individual subscore >1 point Mucosal healing = Mayo endoscopic subscore of 1 point Durability = endpoint met at both weeks 6 and 52
7 C13006 Induction Phase Week 0 Week 6 10 C13006 and C13007 Study Schema Sh Maintenance Phase Week 6 Week 52 Cohort 1 Blinded induction randomization (2:3) Placebo Vedolizumab Placebo No No VDZ Q 4 wks Screening and enrollment (Days 21 to 1) Cohort 1 Enrollment complete? Yes Week 6: Does patient meet defined criteria for response? Placebo Cohort 2 Open label induction treatment Vedolizumab Yes Maintenance randomization (1:1:1) VDZ Q 4 wks VDZ Q 8 wks a The number of patients within each treatment group is an estimate based upon the expected response rate.
8 Disposition iti of Patients, Pti t ITT Populations 8
9 3 Clinical i l Response, Remission, i Mucosal lh Healing at 6 Weeks P< Induction ITT Population P= % P= % CI: Δ 21.7 Δ 11.5 Δ , , , 25.9
10 Clinical Response and Remission at 6 Weeks: Prior Anti TNFα Failure vs No Anti TNFα Exposure Induction ITT Population Patients with Prior Anti TNF Failure Patients Without Anti TNF Exposure (n = 145) (n = 206) % 95% CI: Δ , 32.9 Δ , 22.8 Δ , 39.9 Δ , 30.2
11 2 Pi Primary and Secondary Outcomes Through h 52 Weeks Maintenance ITT Population *** *** *** *** *** *** *** * % ** ** n: Δ26.1 Δ29.1 Δ32.8 Δ28.5 Δ32.0 Δ36.3 Δ11.8 Δ15.3 Δ17.6 Δ31.4 *P<0.05 **P<0.01 ***P<
12 Clinical Remission, Durable Clinical Response at 52 Weeks: Prior Anti TNFα Failure vs No Anti TNFα Exposure Patients with Prior Anti TNF Failure (n = 121) Maintenance ITT Population Patients Without Anti TNF Exposure (n = 224) % 95% CI Q8Wks: 95% CI Q4Wks: Clinical Remission Durable Clinical Response Clinical Remission Durable Clinical Response Δ31.9 Δ29.7 Δ30.7 Δ26.7 Δ26.8 Δ29.0 Δ38.7 Δ , , , , , , , , 44.6
13 C13006: Mean Vedolizumab Serum Concentrations at Weeks 6, 14, 22, 38 and 46 Observed 4
14 Adverse Events Through h Week k52 Maintenance ITT Population Safety Population Placebo N=126 VDZ Q8Wks N=122 VDZ Q4Wks N=125 Placebo* N=275 VDZ N=620 Any adverse event (AE), % Drug related AEs, % AE resulting in discontinuation, % Serious AEs, % Serious infection AEs, % Deaths, n (%) (<1%) * Includes patients who never received VDZ (n=149) and patients who received 2 VDZ induction doses followed by Pbo maintenance (n=126)
15 7 Exposure Adjusted Adverse Events Affecting >5% of VDZ Patients Through Week 52, Safety Population Preferred Term Pbo Rate (N=275) VDZ Rate (N=620) Relative Risk 95% CI Headache , Ulcerative colitis , Nasopharyngitis , Upper respiratory tract infection , Arthralgia , Nausea , Abdominal pain , Anaemia , Fatigue , Cough , Influenza , Any serious AE , Any infection ,
16 Summary and Conclusion Refractory population: approximately one third with anti TNFα failure Compared with placebo: Significantly greater proportion of VDZ treated patients achieved clinical response, remission, and mucosal healing at 6 weeks Significantly greater proportion of VDZ treated patients achieved clinical remission, mucosal healing, and corticosteroid free remission at 52 weeks and durable response and remission (6 and 52 weeks) Similar rates of AEs, serious AEs, and serious infections between VDZ and placebo groups; low rate of sensitization/avas Conclusion: Vdli Vedolizumab bis more effective than placebo as induction and maintenance therapy in patients with moderate to severely active ulcerative colitis (anti TNF exposed and naïve patients) 16
17 Vedolizumab GEMINI CD Efficacy Results C13007 and C13011
18 VedolizumabDevelopment in Crohn s Disease: Key Trial Aspects C13007 Double blind 6 week PLC controlled induction Responders on Vedo randomized to maintenance on 2 dosing regimens of Vedo or PLC Open label induction to enrich maintenance arms 46 week maintenance Limited Anti TNF prior exposure to 50% (not necessarily failure) C13011 Classical double blind 10 week PLC controlled, 2 arms induction Endpoints at weeks 6 and 10 Primarily anti TNF failure patients
19 Pi Primary Endpoints C13007 Simultaneous testing of twoprimary Week 6 endpoints (Hochberg method) Clinical remission (CDAI 150) and Enhanced Clinical Response (CDAI decrease 100 points) at week 6 Test both endpoints simultaneously at p 0.05 If one endpoint negative: test the other endpoint at p The Hochberg approach controls family wise type I error rate at 0.05 (two sided) Remission at Week 6 in TNFα failure patients
20 9 Study Overview: C13007 Total, N=1117 Induction Phase Week 0 Week 6 Maintenance Phase Week 6 Week 52 Cohort 1 Blinded induction randomization Placebo N=148 (2:3) N=370 Vedolizumab N=220 No No Placebo N=148 VDZ Q4 wks N=412 a Screening and enrollment (Days 21 to 1) Cohort 1 Enrollment complete? Week 6: Does patient meet defined d criteria for response? * Yes Cohort 2 Open label induction treatment N=747 Vedolizumab N=747 Yes Maintenance randomization (1:1:1) N=461 Placebo N=153 a VDZ Q4 wks VDZ Q8 wks N=154 a
21 Inclusion Cit Criteriai C13007 Moderately to severely active CD as determined by a CDAI score of 220 to 450 (see Section 15.1) within 7 days prior to the first dose of study drug and 1 of the following: CRP level >2.87 mg/l during the Screening period OR Ileocolonoscopy with photographic documentation of a minimum of 3 nonanastomotic ulcerations (each >0.5 cm in diameter) or 10 aphthous ulcerations (involving a minimum of 10 contiguous cm of intestine) consistent withcd CD, within 4 months prior to randomization OR Fecal calprotectin >250 µg/g stool during the Screening period in conjunction with CT evidence of fixed stenosis or small bowel stenosis with prestenotic dilation should not be included.) C13011 Moderately to severely active CD as determined by a CDAI score of 220 to 400 (see Section 15.1) within 7 days before enrollment and 1 of the following: CRP level > 2.87 mg/l during the Screening period, OR Ileocolonoscopy with photographic documentation of a minimum of 3 nonanastomotic ulcerations (each > 0.5 cm in diameter) or 10 aphthous ulcerations (involving a minimum of 10 contiguous cm of intestine) consistent with CD, within 4 months enterography, MR enterography, contrast enhanced small bowel radiography, or wireless capsule endoscopy revealing Crohn s ulcerations (aphthae not sufficient), within 4 months prior to screening. (Patients with before enrollment, OR Fecal calprotectin >250 µg/g stool during the Screening period in conjunction with computed tomography (CT) enterography, magnetic resonance (MR) enterography, contrast enhanced small bowel radiography, or wireless capsule endoscopy revealing Crohn s ulcerations (aphthae not sufficient), within 4 months before screening. (Patients with evidence of fixed stenosis or small bowel stenosis with prestenotic dilation should not be included.)
22 C13007 Disposition of Patients, ITT Population, Cohort 1 and 2 Randomized d N=368 Placebo N=148 VDZ (I) N=220 VDZ (2) N=747 Completed N=137 (93%) Completed N=199 (90%) Completed N=674 (90%) Discontinued N(%) (7%) (10%) 73 (10%) Adverse Event Lack of Efficacy Consent Withdrawn
23 Results: Primarily Clinical Remission
24 Clinical Remission (95% CI) by Treatment Group at Week 6 ITT C13007 C13011 p=0.02 p=0.048
25 Clinical Remission (95% CI) by Treatment Group at Week 6 Anti TNF Failure and Anti TNF Naive ITT p= C13007 C13011 C13007 C13011 N=70, N=105 N=157, N=158 N=78, N=115 N=50, N=51
26 C13011: Percent of Patients Achieving Clinical Remission Over Time p=0.048 p <0.0001
27 C13007 Vdli Vedolizumab bin Crohn s Disease: Maintenance Results
28 Disposition of Patients, Maintenance Phase, ITT Population Randomized N=461 Placebo N=153 VDZ Q8 Wks N=154 VDZ Q4 Wks N=154 Completed N=64 (42%) Completed N=73 (47%) Completed N=82 (52%) Discontinued Na (%) (58%) (53%) (47%) Adverse Event Lack of Efficacy Other* *Includes protocol violation, withdrawn consent, loss to follow-up, and other reasons.
29 5 Primary and Secondary Outcomes Through 52 Weeks ITT Δ17.4 Δ14.7 Δ13.4 Δ15.3 Δ7.2 Δ2.0 Δ15.9 Δ12.9 *P<0.05; **P<0.01 CS tapering began in responders at 6 weeks; for others, as soon as a clinical response was achieved.
30 8 C13007: Mean Vedolizumab Serum Concentrations at Weeks 6, 14, 22, 38 and 46 Observed
31 CLINICAL POSITIONING OF CURRENT BIOLOGICS UC Anti TNF Anti integrin Induction / maintenance UC / / Steroid refractory fulminant UC Steroid refractory UC (post hoc) Early UC / Late UC (post hoc) Sft Safety in UC Favourable efficacy and/or safety profile Less favourable profile CD, Crohn s disease; IBD, inflammatory bowel disease; UC, ulcerative colitis Danese S, Panés J. Gastroenterology 2014; Epub 14 September (DOI: /j.gastro ). 31
32 CLINICAL POSITIONING OF CURRENT 1 BIOLOGICS UC CD Anti TNF Anti integrin Induction / maintenance UC / / Steroid refractory fulminant UC Steroid refractory UC (post hoc) Early UC / Late UC (post hoc) Safety in UC Induction / maintenance luminal CD / / Perianal fistulising CD Infliximab Early luminal / Late luminal CD (post hoc) / / Favourable efficacy and/or safety profile Less favourable profile CD, Crohn s disease; IBD, inflammatory bowel disease; UC, ulcerative colitis Danese S, Panés J. Gastroenterology 2014; Epub 14 September (DOI: /j.gastro ). 32
33 Grazie
34 CLINICAL POSITIONING OF CURRENT 1 BIOLOGICS OG UC CD Anti TNF Anti integrin Induction / maintenance UC / / Steroid refractory fulminant UC Steroid refractory UC (post hoc) Early UC / Late UC (post hoc) Safety in UC Induction / maintenance luminal lcd / / Perianal fistulising CD Infliximab Early luminal / Late luminal CD (post / / hoc) Favourable efficacy and/or safety profile Less favourable profile CD, Crohn s disease; IBD, inflammatory bowel disease; UC, ulcerative colitis Danese S, Panés J. Gastroenterology 2014; Epub 14 September (DOI: /j.gastro ). 34
35 2 UC: Primary and Secondary Outcomes Through 52 Weeks Maintenance ITT Population *** *** *** *** *** *** *** * % ** ** n: Δ26.1 Δ29.1 Δ32.8 Δ28.5 Δ32.0 Δ36.3 Δ11.8 Δ15.3 Δ17.6 Δ31.4 *P<0.05 **P<0.01 ***P<0.0001
36 3 P< UC Induction ITT Population P= % P= % CI: Δ 21.7 Δ 11.5 Δ , , , 25.9
37 4 C13006: Mean Vedolizumab Serum Concentrations at Weeks 6, 14, 22, 38 and 46 Observed
38 5 CD Primary and Secondary Outcomes Through 52 Weeks ITT Δ17.4 Δ14.7 Δ13.4 Δ15.3 Δ15.9 Δ12.9 *P<0.05; **P<0.01 CS tapering began in responders at 6 weeks; for others, as soon as a clinical response was achieved. Δ7.2 Δ2.0
39 6 Steps leukocyte recruitment Fiorino G. et al. 2010
40 7 Exposure Adjusted Adverse Events Affecting>5% of VDZ Patients Through Week 52, Safety Population Preferred Term Pbo Rate (N=275) VDZ Rate (N=620) Relative Risk 95% CI Headache , Ulcerative colitis , Nasopharyngitis , Upper respiratory tract infection , Ath Arthralgia li , Nausea , Abdominal pain , Anaemia , Fatigue , Cough , Influenza , Any serious AE , Any infection ,
41 C13007: Mean Vedolizumab Serum 8 Concentrations ti at Weeks 6, 14, 22, 38 and 46 Observed
42 9 Study Overview: C13007 Total, N=1117 Induction Phase Week 0 Week 6 Maintenance Phase Week 6 Week 52 Cohort 1 Placebo Placebo Blinded N=148 N=148 induction randomization (2:3) N=370 Vedolizumab N=220 VDZ Q4 wks No No N=412 a Screening and enrollment (Days 21 to 1) Cohort 1 Enrollment complete? Yes Week 6: Does patient meet defined criteria for response? * Placebo N=153 a Cohort 2 Open label induction treatment N=747 Vedolizumab N=747 Yes Maintenance randomization (1:1:1) N=461 VDZ Q4 wks VDZ Q8 wks N=154 a
43 C13006 and C13007 Study 10 Schema Induction Phase Maintenance Phase Week 0 Week 6 Week 6 Week 52 Cohort 1 Placebo Placebo Blinded induction randomization (2:3) Vedolizumab No No VDZ Q 4 wks Screening and enrollment (Days 21 to 1) Cohort 1 Enrollment complete? Yes Week 6: Does patient meet defined criteria for response? Placebo Cohort 2 Open label induction treatment Vedolizumab Yes Maintenance randomization (1:1:1) VDZ Q 4 wks VDZ Q 8 wks a The number of patients within each treatment group is an estimate based upon the expected response rate.
New treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy
New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationBiologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
More informationPredicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationSelective leucocyte trafficking inhibitors for treatment of IBD
Selective leucocyte trafficking inhibitors for treatment of IBD Séverine Vermeire MD, PhD Department of Gastroenterology University Hospitals Leuven Belgium Migration of Leucocytes plays a key role in
More informationBiologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationTumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review)
Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review) Behm BW, Bickston SJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More informationLong-term Efficacy of Vedolizumab for Crohn s Disease
Journal of Crohn's and Colitis, 217, 412 424 doi:1.193/ecco-jcc/jjw176 Advance Access publication September 28, 216 Original Article Original Article Long-term Efficacy of Vedolizumab for Crohn s Disease
More informationVedolizumab: policing leukocyte traffic
Oxford Inflammatory Bowel Disease MasterClass Vedolizumab: policing leukocyte traffic Dr Brian Feagan, London, Canada Vedolizumab : Policing Lymphocyte Traficking Brian G. Feagan Professor of Medicine,
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More information1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: May 1, 2018 Last Revised: April 18, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationTherapies for IBD: the Pipeline. New Therapeutic Agents in IBD
Therapies for IBD: the Pipeline New Therapeutic Agents in IBD William J. Sandborn, MD Professor & Chief, Division of Gastroenterology Director, UCSD IBD Center Budesonide Oral MMX budesonide Rectal budesonide
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION VEDOLIZUMAB (Entyvio Takeda Canada Inc.) Indication: Ulcerative Colitis Recommendation: The CADTH Canadian Drug Expert Committee (CDEC) recommends
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: June 9, 2019* Last Revised: Feb. 12, 2019 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More information2nd Nottingham IBD Masterclass, 2017
2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory
More informationAnti tumor necrosis factor (TNF) agents have
Achieving Clinical Response and Remission in Moderate-to-Severe Ulcerative Colitis With Golimumab Sandborn WJ, Feagan BG, Marano C, et al; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationFOR UK NURSING MEDIA Embargoed until: 00:01 GMT, Friday 13 March 2015
Contact: Ross Selby Takeda UK Ltd Email ross.selby@takeda.com News Release FOR UK NURSING MEDIA Embargoed until: 00:01 GMT, Friday 13 March 2015 World s first gut-selective treatment for ulcerative colitis
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationvedolizumab 300mg powder for concentrate for solution for infusion (Entyvio ) SMC No. (1064/15) Takeda UK Ltd
vedolizumab 300mg powder for concentrate for solution for infusion (Entyvio ) SMC No. (1064/15) Takeda UK Ltd 05 June 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationOptimizing Therapies for Severe Ulcerative Colitis October 19, 2014
Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014 Ellen J. Scherl, MD, FACP, FACG, AGAF, FASGE, NYSGEF Director Jill Roberts Center for Inflammatory Bowel Disease Jill Roberts IBD Research
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationCrohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?
Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationUse of extrapolation in small clinical trials:
Use of extrapolation in small clinical trials: Infliximab for pediatric ulcerative colitis Jessica J. Lee, MD, MMSc Medical Officer Division of Gastroenterology and Inborn Errors Products CDER/ FDA 1 Learning
More informationEfficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn s Disease Patients Stratified by Age
Adv Ther (2017) 34:542 559 DOI 10.1007/s12325-016-0467-6 ORIGINAL RESEARCH Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn s Disease Patients Stratified by Age Vijay Yajnik. Nabeel Khan.
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationINFLAMMATORY BOWEL DISEASE
1. Medical Condition INFLAMMATORY BOWEL DISEASE (IBD) specifically includes Crohn s disease (CD) and ulcerative colitis (UC) but also includes IBD unclassified (IBDu), seen in about 10% of cases. These
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationEmerging Therapies in IBD 2006
Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationDDW abstract review: Crohn s disease/ibd. Jesse Siffledeen Edmonton. May 26-28, 2017 Fairmont Chateau Lake Louise, Lake Louise, Alberta
DDW abstract review: Crohn s disease/ibd Jesse Siffledeen Edmonton May 26-28, 2017 Fairmont Chateau Lake Louise, Lake Louise, Alberta Disclosure of Commercial Support Potential for conflict(s) of interest:
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationCAG Symposium: Management of IBD in 2018
CAG Symposium: Management of IBD in 2018 Waqqas Afif, MD, M. Sc., FRCPC, Associate Professor, Department of Medicine Division of Gastroenterology McGill University Health Center X X X X X CanMEDS Roles
More informationAAPS NBC 2016 IBD Symposium
AAPS NBC 2016 IBD Symposium Steven W Martin, PhD Group,, Pfizer, Cambridge, MA MAdCAM plays a central role in lymphocyte homing to the gut Adapted from Cheroutre and Madakamutil 2004 Anti-MAdCAM Mechanistic
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationSUPPLEMENTAL MATERIALS
SUPPLEMENTAL MATERIALS Intensity of Adverse Events The intensity for each adverse (AE) was defined by the study investigator as mild, moderate, or severe according to the following criteria: Mild: Awareness
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationInflammatory bowel disease (IBD) Overview of the Paediatric investigation plans. Presented by: Richard Veselý. An agency of the European Union
Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans Presented by: Richard Veselý An agency of the European Union Adalimumab - Crohn s disease Indication: Treatment of severe,
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationPEDIATRIC INFLAMMATORY BOWEL DISEASE
PEDIATRIC INFLAMMATORY BOWEL DISEASE Alexis Rodriguez, MD Pediatric Gastroenterology Advocate Children s Hospital Disclosers Abbott Nutrition - Speaker Inflammatory Bowel Disease Chronic inflammatory disease
More informationThe role of vedolizumab in patients with moderate-to-severe Crohn s disease and ulcerative colitis
635081TAG0010.1177/1756283X16635081Therapeutic Advances in GastroenterologyN Shahidi, B Bressler research-article2016 Therapeutic Advances in Gastroenterology Review The role of vedolizumab in patients
More informationBiologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA
Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 285.8 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationDavid Y. Graham, MD Baylor College of Medicine, Houston TX, USA
Phase III Randomized, Double Blind, Placebo- Controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Add-On Fixed-Dose Anti- Mycobacterial Therapy (RHB-104) in Moderately to
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationNorthern Treatment Advisory Group. Biologic drugs for treatment-refractory moderately to severely active ulcerative colitis
Northern Treatment Advisory Group Biologic drugs for treatment-refractory moderately to severely active ulcerative colitis Lead author: Dominic McDermott Regional Drug & Therapeutics Centre (Newcastle)
More informationNew clinical study also provides data for Entyvio in inducing complete mucosal healing and endoscopic remission, particularly in bio-naïve patients
News Release Embargoed until February 16, 2018 at 17:00 CET Entyvio (vedolizumab) Shows Higher Rates of Mucosal Healing Versus TNFα-Antagonist Therapy in Ulcerative Colitis and Crohn s Disease Patients
More informationSTELARA (ustekinumab) Clinical Study Report CNTO1275CRD3001
SYNOPSIS Name of Sponsor/Company Janssen Research & Development* Name of Investigational Product STELARA (ustekinumab) * Janssen Research & Development is a global organization that operates through different
More information4/16/2018. Updates in Crohn s Disease. Disclosures. Learning Objectives. Crohn s Disease is Progressive and Destructive
4/16/218 Disclosures Updates in Crohn s Disease David T. Rubin, MD Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition University of Chicago Consultant
More informationVedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn s disease
Virginia Commonwealth University VCU Scholars Compass VCU Health Publications VCU Health 2015 Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn s disease Lauren N. Cherry Virginia
More informationSynopsis (C0168T37 ACT 1)
() Module 5.3 Protocol: CR004777 EudraCT No.: Not Applicable Title of the study: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients with
More informationU of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-severe Crohn s Disease Refractory to Anti-TNFα: UNITI-1 WJ Sandborn 1,
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationUlcerative colitis (UC) is a chronic inflammatory. Therapeutic Options in Steroid-Refractory Acute Severe Ulcerative Colitis.
Therapeutic Options in Steroid-Refractory Acute Severe Ulcerative Colitis Wojciech Blonski, MD, PhD, Prashant R. Mudireddy, MD, Anna M. Buchner, MD, PhD, and Gary R. Lichtenstein, MD Abstract Objective:
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationAchieving Success in Ulcerative Colitis: the Role of Infliximab
Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationDr. Elmer Schabel, MD. Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany (No conflicts of interest)
EMA workshop on the development of new medicinal products for the treatment of ulcerative colitis and Crohn s disease Overview of authorised medicines for IBD in Europe - previous regulatory positions
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More informationIBD 101. Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition
IBD 101 Ronen Stein, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Objectives Identify factors involved in the development of inflammatory bowel
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationProgress in Inflammatory Bowel Disease
Progress in Inflammatory Bowel Disease Gary R Lichtenstein, MD Director, Center for IBD University of Pennsylvania School of Medicine Hospital of the University of PA Philadelphia, PA Disclosure Research,
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION VEDOLIZUMAB (Entyvio Takeda Canada Inc.) Indication: Crohn s Disease Recommendation: The CADTH Canadian Drug Expert Committee (CDEC) recommends
More informationCase Example: Exposure Response to Support Extrapolation of Efficacy in Pediatric Ulcerative Colitis
Case Example: Exposure Response to Support Extrapolation of Efficacy in Pediatric Ulcerative Colitis Kerry Jo Lee, MD Medical Officer Division of Gastroenterology and Inborn Error Products Office of New
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationIntroduction. Toshifumi Hibi 1 Yuya Imai
J Gastroenterol (2017) 52:1101 1111 DOI 10.1007/s00535-017-1326-1 ORIGINAL ARTICLE ALIMENTARY TRACT Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely
More informationHighlights of DDW 2015: Crohn s disease
Highlights of DDW 2015: Crohn s disease Mark S. Silverberg, MD, PhD, FRCPC Associate Professor of Medicine, University of Toronto Staff Gastroenterologist, Mount Sinai Hospital Senior Investigator, Lunenfeld-Tanenbaum
More information